KCNA3 and neoplasm: This correlated well with tumour uptake of the Kv1.3-targeting radiopharmaceutical [18F]AlF-NOTA-KCNA3P with significantly higher retention in tumours responsive to αPD1 or combined αPD1 + αCTLA4 therapy compared to TNRs (Table 1, Figure 3).